[
  {
    "ts": null,
    "headline": "Kymera initiated at Outperform on potential of lead skin drug",
    "summary": "Investing.com --Analysts initiated coverage of Kymera Therapeutics with an Outperform rating and $70 price target, citing confidence in the company’s lead experimental drug for atopic dermatitis.",
    "url": "https://finnhub.io/api/news?id=d1b56a66aacc7fd682611da9c166602877a39e66f94fab178989445da029b9ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758043802,
      "headline": "Kymera initiated at Outperform on potential of lead skin drug",
      "id": 136773686,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Investing.com --Analysts initiated coverage of Kymera Therapeutics with an Outperform rating and $70 price target, citing confidence in the company’s lead experimental drug for atopic dermatitis.",
      "url": "https://finnhub.io/api/news?id=d1b56a66aacc7fd682611da9c166602877a39e66f94fab178989445da029b9ab"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals (REGN) Releases Results From EMPOWER-Lung 3 trial",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best NASDAQ Stocks to Buy with Huge Upside Potential. On September 9, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced five-year follow-up results from its phase 3 EMPOWER-Lung 3 trial. The trial tested Libtayo combined with platinum-based chemotherapy versus chemotherapy alone and was meant for adults with advanced or metastatic […]",
    "url": "https://finnhub.io/api/news?id=59bdb2303952b5a989c63326c7eccdbfdbc789d604a8d72aa85776636c6e590e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758040955,
      "headline": "Regeneron Pharmaceuticals (REGN) Releases Results From EMPOWER-Lung 3 trial",
      "id": 136773687,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best NASDAQ Stocks to Buy with Huge Upside Potential. On September 9, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced five-year follow-up results from its phase 3 EMPOWER-Lung 3 trial. The trial tested Libtayo combined with platinum-based chemotherapy versus chemotherapy alone and was meant for adults with advanced or metastatic […]",
      "url": "https://finnhub.io/api/news?id=59bdb2303952b5a989c63326c7eccdbfdbc789d604a8d72aa85776636c6e590e"
    }
  },
  {
    "ts": null,
    "headline": "Drug developer Dualitas launches $65 million funding round",
    "summary": "(Reuters) -San Francisco-based biotech Dualitas Therapeutics said on Tuesday it has launched a $65 million early-stage funding round, and plans to use the proceeds to develop next-generation therapies for immunity-related diseases.  The series A funding round will be co-led by Versant Ventures and Qiming Venture Partners USA, with pharmaceutical major Eli Lilly also participating, Dualitas said.  The company did not disclose its valuation in the funding round.",
    "url": "https://finnhub.io/api/news?id=881acb8e3ec0da75c8685720d14818e1f016a46b756a1e6e7dcec442db9db8dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758024232,
      "headline": "Drug developer Dualitas launches $65 million funding round",
      "id": 136773229,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "(Reuters) -San Francisco-based biotech Dualitas Therapeutics said on Tuesday it has launched a $65 million early-stage funding round, and plans to use the proceeds to develop next-generation therapies for immunity-related diseases.  The series A funding round will be co-led by Versant Ventures and Qiming Venture Partners USA, with pharmaceutical major Eli Lilly also participating, Dualitas said.  The company did not disclose its valuation in the funding round.",
      "url": "https://finnhub.io/api/news?id=881acb8e3ec0da75c8685720d14818e1f016a46b756a1e6e7dcec442db9db8dd"
    }
  },
  {
    "ts": null,
    "headline": "Senhwa Biosciences' CX-5461 Teams Up with Global PD-1 Leaders to Enter the Immunotherapy Arena, Targeting Multi-Billion Dollar Global Market",
    "summary": "Senhwa Biosciences, Inc. (TPEx: 6492, \"Senhwa\") today announced its official entry into the fast-growing global immuno-oncology market. The Company's novel investigational drug Pidnarulex (CX-5461) will be evaluated in combination with the approved PD-1 inhibitor Cemiplimab (Libtayo®), provided by Sanofi and Regeneron Pharmaceuticals, in a Phase 1/2 clinical trial for patients with microsatellite-stable colorectal cancer (MSS CRC) who are refractory to immune checkpoint inhibitors.",
    "url": "https://finnhub.io/api/news?id=55e4f19d8f2d41929a30c718d28468a45944b5ed24ff7aa37ff8bc573e298992",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758011700,
      "headline": "Senhwa Biosciences' CX-5461 Teams Up with Global PD-1 Leaders to Enter the Immunotherapy Arena, Targeting Multi-Billion Dollar Global Market",
      "id": 136773689,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Senhwa Biosciences, Inc. (TPEx: 6492, \"Senhwa\") today announced its official entry into the fast-growing global immuno-oncology market. The Company's novel investigational drug Pidnarulex (CX-5461) will be evaluated in combination with the approved PD-1 inhibitor Cemiplimab (Libtayo®), provided by Sanofi and Regeneron Pharmaceuticals, in a Phase 1/2 clinical trial for patients with microsatellite-stable colorectal cancer (MSS CRC) who are refractory to immune checkpoint inhibitors.",
      "url": "https://finnhub.io/api/news?id=55e4f19d8f2d41929a30c718d28468a45944b5ed24ff7aa37ff8bc573e298992"
    }
  }
]